News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Goodwin Biotechnology says making trial supplies of Q Therapeutics’ amyotrophic lateral sclerosis (ALS) cell therapy meant overcoming considerable technical hurdles.
There are plenty of opportunities for multiple players in the biosimialr market, says Epirus after striking a commercialisation deal with Polpharma.
Agilent and A*STAR have partnered to create quicker, more accurate ways of testing the sugar content of therapeutic proteins and monoclonal antibodies (mAbs) that are tailored for commercial producers.